Thermo Fisher Scientific has released Watson Lims 7.4 to provide savings for pharmaceutical companies and contract research organisations (CROs) involved in drug discovery and development.
The latest release of Watson Lims is designed to deliver improved efficiencies and reduced validation time, contributing to time and cost savings and improved time to market.
A key feature of the latest release is a function that simplifies daily workflow for bioanalytical laboratories by delivering enhanced functionality for incurred sample reanalysis (ISR).
ISR has become an accepted way to assess the quality of bioanalytical assays and is widely accepted within the pharmaceutical industry and by regulatory agencies.
Watson Lims 7.4 allows researchers to perform incurred sample reanalysis on an individual sample basis, and eliminates mandatory repeat runs for bioanalytical samples.
New ISR reporting features provide comparison methods with built-in calculations to enable flexible, preconfigured reporting of ISR results using templates.
Additional features of Watson 7.4 include performance improvements in the Design Summary Report, delivering an increase in reporting speed, enhancements to the Immune Response Module and the Watson Web Services Library.
These features are designed to enable users to more easily manage the status of samples, choose samples with a positive screen or a positive titre result for use in subsequent assay tests, and import samples and sample-related information from external applications.
Watson Lims 7.4 also includes a built-in data interchange with the company's TSQ Series mass spectrometers, allowing for direct data acquisition, peak integration and re-integration, storage, archiving and reporting of raw data, all under the control of Watson's centralised Oracle database repository.
Watson's connectivity to the TSQ Series mass spectrometers eliminates manual verification of LC/MS data transfers, and provides a single audit trail for QA and the FDA.
This end-to-end solution delivers enhanced functionality for data security and chain of custody for regulatory compliance, as well as a lower cost of ownership due to the reduced validation burden.
The company said that Watson's direct data acquisition from the TSQ Series LC/MS instruments, together with its new incurred sample re-analysis functionality and reporting, delivers time savings to pharmaceutical companies and CROs, allowing them to bring drugs to market faster for less cost.
Thermo Fisher Scientific will exhibit Watson Lims 7.4 at the Annual Conference of the American Society for Mass Spectrometry (ASMS) in Philadelphia from 31 May - 4 June.
